clobazam has been researched along with Drug Refractory Epilepsy in 22 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 12-year-old boy with intractable epilepsy had tonic and atonic seizures despite treatment with valproic acid (3000mg/day), levetiracetam (3000mg/day) and clobazam (40mg/day)." | 7.83 | Aggravation of atonic seizures by rufinamide: A case report. ( Aydın, A; Aydınlı, N; Bektaş, G; Çalışkan, M; Özmen, M; Pembegül Yıldız, E; Tatlı, B, 2016) |
| "Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam." | 7.81 | Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015) |
| " Other factors, including dosage and clobazam co-therapy, were significantly associated with a greater effect on seizure control and side effects of CBD." | 7.01 | Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023) |
| "The average number of seizures per month during the previous 3 months before CNB treatment was 19." | 5.91 | Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023) |
| "ANT stimulation and seizure freedom were associated with distinct, dissimilar spectral changes in RNS-derived electrophysiology." | 5.91 | Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023) |
| "Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures." | 5.48 | Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018) |
| "Clobazam (CLB) is a well characterized antiepileptic drug (AED) that differs from other benzodiazepines by its basic chemical structure and pharmacodynamic properties." | 5.43 | Effects of clobazam for treatment of refractory status epilepticus. ( Gerner, ST; Geyer, A; Gollwitzer, S; Hamer, HM; Huttner, HB; Knappe, RU; Kuramatsu, JB; Madžar, D, 2016) |
| " The mean baseline seizure frequency before initiation of clobazam was 2 (range 1-30) seizures per month." | 4.31 | Tolerability of clobazam as add-on therapy in patients aged 50 years and older with drug-resistant epilepsy. ( Bunch, ME; Frawley, B; Lynch, TM; Nagarajan, E, 2023) |
| "We identified a significant decrease in the serum concentrations of clobazam, desmethylclobazam, and lamotrigine following a 12-week ketogenic diet intervention in children with drug resistant epilepsy." | 4.31 | Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet. ( Gervin, K; Iversen, PO; Kverneland, M; Landmark, CJ; Pedersen, S; Rudi, K; Selmer, KK, 2023) |
| "Cannabidiol (CBD) has been shown to reduce seizures among patients with refractory epilepsies of various etiologies in recent clinical trials and an expanded access program (EAP)." | 4.02 | The long-term efficacy of cannabidiol in the treatment of refractory epilepsy. ( Bruno, PL; Fleming, B; Grinspoon, R; Patel, S; Skirvin, LA; Thiele, EA; Wade, C; Wolper, E, 2021) |
| "A 12-year-old boy with intractable epilepsy had tonic and atonic seizures despite treatment with valproic acid (3000mg/day), levetiracetam (3000mg/day) and clobazam (40mg/day)." | 3.83 | Aggravation of atonic seizures by rufinamide: A case report. ( Aydın, A; Aydınlı, N; Bektaş, G; Çalışkan, M; Özmen, M; Pembegül Yıldız, E; Tatlı, B, 2016) |
| "Clobazam treatment tailored to the timing of patient's seizures may improve seizure control." | 3.83 | Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsy. ( Fernández, IS; Jackson, M; Kadish, NE; Klehm, J; Loddenkemper, T; Manganaro, S; Thome-Souza, S, 2016) |
| "Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam." | 3.81 | Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015) |
| "Epidiolex® (CBD) is FDA-approved for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC)." | 3.30 | Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. ( Felton, E; Georgieva, D; Gidal, BE; Hartkopf, K; Hawk, L; Hsu, D; Langley, J; Margolis, A; Struck, A, 2023) |
| " Other factors, including dosage and clobazam co-therapy, were significantly associated with a greater effect on seizure control and side effects of CBD." | 3.01 | Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023) |
| " In the secondary analyses, participants were divided into groups depending on whether they were taking at least 1/4 of the other AEDs shown to interact with CBD (iAED)." | 2.90 | Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. ( Ampah, SB; Bebin, EM; Cutter, GR; Gaston, TE; Grayson, LP; Liu, Y; Szaflarski, JP, 2019) |
| " Cannabidiol is rapidly absorbed and its bioavailability increases when administered with high fat meals." | 2.66 | Clinical pharmacology of cannabidiol in refractory epilepsy. ( Cáceres-Guido, P; Maldonado, C; Riva, N; Schaiquevich, P; Vázquez, M, 2020) |
| "The average number of seizures per month during the previous 3 months before CNB treatment was 19." | 1.91 | Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023) |
| "ANT stimulation and seizure freedom were associated with distinct, dissimilar spectral changes in RNS-derived electrophysiology." | 1.91 | Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023) |
| "Mean reduction in weekly seizure frequency was greater at the best point of seizure control within the first year than at two months of treatment with CBD, regardless of concomitant CLB usage (all p > 0." | 1.56 | Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam. ( Anagnos, CJ; Bruno, PL; Savage, TE; Skirvin, LA; Sourbron, J; Thiele, EA; Wolper, ES, 2020) |
| "Conclusions Depressive disorders are common, underdiagnosed and undertreated in patients with refractory MTLE." | 1.48 | Depressive disorders in patients with pharmaco-resistant mesial temporal lobe epilepsy. ( Cendes, F; de Oliveira Cardoso, TAM; Gonçalves, EB; Yasuda, CL, 2018) |
| "Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures." | 1.48 | Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018) |
| "Nocturnal frontal lobe epilepsy (NFLE) is an idiopathic partial epilepsy with a family history in about 25% of cases, with autosomal dominant inheritance (autosomal dominant NFLE [ADNFLE])." | 1.46 | Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy. ( Aroni, S; Marrosu, F; Melis, M; Milioli, G; Muntoni, AL; Parrino, L; Pillolla, G; Pistis, M; Puligheddu, M; Sagheddu, C; Terzano, GM, 2017) |
| "Clobazam (CLB) is an antiepileptic drug that is metabolized to the major metabolite N-desmethylclobazam (N-CLB)." | 1.46 | Correlating blood and urinary concentrations of clobazam doses in Japanese children and adolescents with intractable epilepsy. ( Ishida, T; Ishii, M; Iwasaki, T; Nonoda, Y; Toki, T, 2017) |
| "Clobazam (CLB) is a well characterized antiepileptic drug (AED) that differs from other benzodiazepines by its basic chemical structure and pharmacodynamic properties." | 1.43 | Effects of clobazam for treatment of refractory status epilepticus. ( Gerner, ST; Geyer, A; Gollwitzer, S; Hamer, HM; Huttner, HB; Knappe, RU; Kuramatsu, JB; Madžar, D, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 12 (54.55) | 2.80 |
| Authors | Studies |
|---|---|
| Talwar, A | 1 |
| Estes, E | 1 |
| Aparasu, R | 1 |
| Reddy, DS | 1 |
| Georgieva, D | 1 |
| Langley, J | 1 |
| Hartkopf, K | 1 |
| Hawk, L | 1 |
| Margolis, A | 1 |
| Struck, A | 1 |
| Felton, E | 1 |
| Hsu, D | 1 |
| Gidal, BE | 1 |
| Nagarajan, E | 1 |
| Lynch, TM | 1 |
| Frawley, B | 1 |
| Bunch, ME | 1 |
| Pedersen, S | 1 |
| Kverneland, M | 1 |
| Rudi, K | 1 |
| Gervin, K | 1 |
| Landmark, CJ | 1 |
| Iversen, PO | 1 |
| Selmer, KK | 1 |
| Serrano-Castro, PJ | 1 |
| Rodríguez-Uranga, JJ | 1 |
| Cabezudo-García, P | 1 |
| García-Martín, G | 1 |
| Romero-Godoy, J | 1 |
| Estivill-Torrús, G | 1 |
| Ciano-Petersen, NL | 1 |
| Oliver, B | 1 |
| Ortega-Pinazo, J | 1 |
| López-Moreno, Y | 1 |
| Aguilar-Castillo, MJ | 1 |
| Gutierrez-Cardo, AL | 1 |
| Ramírez-García, T | 1 |
| Sanchez-Godoy, L | 1 |
| Carreño, M | 1 |
| Skelton, HM | 1 |
| Brandman, DM | 1 |
| Bullinger, K | 1 |
| Isbaine, F | 1 |
| Gross, RE | 1 |
| Savage, TE | 1 |
| Sourbron, J | 1 |
| Bruno, PL | 2 |
| Skirvin, LA | 2 |
| Wolper, ES | 1 |
| Anagnos, CJ | 1 |
| Thiele, EA | 2 |
| Mandelbaum, DE | 1 |
| Lattanzi, S | 1 |
| Brigo, F | 1 |
| Trinka, E | 1 |
| Schaiquevich, P | 1 |
| Riva, N | 1 |
| Maldonado, C | 1 |
| Vázquez, M | 1 |
| Cáceres-Guido, P | 1 |
| Villanueva, V | 1 |
| Carreño-Martínez, M | 1 |
| Gil Nagel-Rein, A | 1 |
| López-González, FJ | 1 |
| Patel, S | 1 |
| Grinspoon, R | 1 |
| Fleming, B | 1 |
| Wade, C | 1 |
| Wolper, E | 1 |
| Puligheddu, M | 1 |
| Melis, M | 1 |
| Pillolla, G | 1 |
| Milioli, G | 1 |
| Parrino, L | 1 |
| Terzano, GM | 1 |
| Aroni, S | 1 |
| Sagheddu, C | 1 |
| Marrosu, F | 1 |
| Pistis, M | 1 |
| Muntoni, AL | 1 |
| Gonçalves, EB | 1 |
| de Oliveira Cardoso, TAM | 1 |
| Yasuda, CL | 1 |
| Cendes, F | 1 |
| Porcari, GS | 1 |
| Fu, C | 1 |
| Doll, ED | 1 |
| Carter, EG | 1 |
| Carson, RP | 1 |
| Incecik, F | 1 |
| Ozcanyüz, DG | 1 |
| Gaston, TE | 1 |
| Bebin, EM | 1 |
| Cutter, GR | 1 |
| Ampah, SB | 1 |
| Liu, Y | 1 |
| Grayson, LP | 1 |
| Szaflarski, JP | 1 |
| Trivisano, M | 1 |
| Specchio, N | 1 |
| Vigevano, F | 1 |
| Bektaş, G | 1 |
| Çalışkan, M | 1 |
| Aydın, A | 1 |
| Pembegül Yıldız, E | 1 |
| Tatlı, B | 1 |
| Aydınlı, N | 1 |
| Özmen, M | 1 |
| Thome-Souza, S | 1 |
| Klehm, J | 1 |
| Jackson, M | 1 |
| Kadish, NE | 1 |
| Manganaro, S | 1 |
| Fernández, IS | 1 |
| Loddenkemper, T | 1 |
| Iwasaki, T | 1 |
| Nonoda, Y | 1 |
| Ishida, T | 1 |
| Toki, T | 1 |
| Ishii, M | 1 |
| Madžar, D | 1 |
| Geyer, A | 1 |
| Knappe, RU | 1 |
| Gollwitzer, S | 1 |
| Kuramatsu, JB | 1 |
| Gerner, ST | 1 |
| Hamer, HM | 1 |
| Huttner, HB | 1 |
3 reviews available for clobazam and Drug Refractory Epilepsy
| Article | Year |
|---|---|
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Topics: Adult; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug Resistant Epilepsy; Epilepsies, Myoclonic | 2023 |
Clinical pharmacology of cannabidiol in refractory epilepsy.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Drug Resistant Epilepsy; Humans; Quality of Life | 2020 |
New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
Topics: Administration, Oral; Adolescent; Algorithms; Anticonvulsants; Cannabidiol; Child; Child, Preschool; | 2021 |
2 trials available for clobazam and Drug Refractory Epilepsy
| Article | Year |
|---|---|
Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Drug Resistant E | 2023 |
Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
Topics: Adolescent; Adult; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug Interactions; Drug Resistant | 2019 |
17 other studies available for clobazam and Drug Refractory Epilepsy
| Article | Year |
|---|---|
Tolerability of clobazam as add-on therapy in patients aged 50 years and older with drug-resistant epilepsy.
Topics: Aged; Anticonvulsants; Benzodiazepines; Clobazam; Drug Resistant Epilepsy; Drug Therapy, Combination | 2023 |
Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet.
Topics: Anticonvulsants; Child; Clobazam; Diet, Ketogenic; Drug Resistant Epilepsy; Epilepsy; Humans; Infant | 2023 |
Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies.
Topics: Clobazam; Drug Resistant Epilepsy; Epilepsy; gamma-Aminobutyric Acid; Humans; Precision Medicine; Pr | 2023 |
Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography.
Topics: Biomarkers; Clobazam; Deep Brain Stimulation; Drug Resistant Epilepsy; Electrocorticography; Epileps | 2023 |
Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
Topics: Adolescent; Adult; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Drug Resistant E | 2020 |
Re: Efficacy of Cannabidiol in Subjects with Refractory Epilepsy Relative to Concomitant Use of Clobazam.
Topics: Anticonvulsants; Benzodiazepines; Cannabidiol; Clobazam; Drug Resistant Epilepsy; Humans; Seizures | 2022 |
Cannabidiol efficacy and clobazam coadministration: Where do we stand now?
Topics: Anticonvulsants; Cannabidiol; Clobazam; Drug Resistant Epilepsy; Humans | 2020 |
The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
Topics: Adolescent; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Dose-Response Relations | 2021 |
Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy.
Topics: Adult; Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Disease Models, Animal; D | 2017 |
Depressive disorders in patients with pharmaco-resistant mesial temporal lobe epilepsy.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Benzodiazepines; Carbamazepine; Clobazam; Depressive | 2018 |
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Topics: Adolescent; Anticonvulsants; Attention; Cannabidiol; Cannabis; Child; Child, Preschool; Clobazam; Dr | 2018 |
Unusual side effects due to clobazam: a case report with edema of the extremities.
Topics: Anticonvulsants; Child; Clobazam; Drug Resistant Epilepsy; Edema; Extremities; Humans; Male | 2018 |
Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy.
Topics: Age of Onset; Anticonvulsants; Autistic Disorder; Benzodiazepines; Cadherins; Child; Clobazam; Cogni | 2015 |
Aggravation of atonic seizures by rufinamide: A case report.
Topics: Anticonvulsants; Benzodiazepines; Brain; Child; Clobazam; Drug Resistant Epilepsy; Drug Therapy, Com | 2016 |
Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsy.
Topics: Anticonvulsants; Benzodiazepines; Case-Control Studies; Child; Child, Preschool; Clobazam; Drug Chro | 2016 |
Correlating blood and urinary concentrations of clobazam doses in Japanese children and adolescents with intractable epilepsy.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Asian People; Benzodiazepines; Child; Child, Pres | 2017 |
Effects of clobazam for treatment of refractory status epilepticus.
Topics: Aged; Anticonvulsants; Benzodiazepines; Clobazam; Drug Resistant Epilepsy; Female; Humans; Male; Mid | 2016 |